mys-1 Antibody
Product Specs
Components: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
The mys-1 antibody targets a protein that is likely a catalytic subunit of the Tip60 chromatin-remodeling complex. This protein may acetylate histones H4 and H2A within nucleosomes. It plays a role in determining the cell fates of vulval and distal tip cell (DTC) precursors.
Further research indicates a role for mys-1 in a histone-modifying complex. This complex, composed of the LSY-12 MYST-type histone acetyltransferase, the ING-family protein LSY-13, and the PHD/bromodomain protein LIN-49, is essential for initiating and maintaining lateralized gene expression within the gustatory system. PMID: 20923973
Q&A
Here’s a structured FAQ collection for researchers working with My-1 Antibody, organized by scientific depth and methodological focus, based on peer-reviewed studies and technical guidelines:
Advanced Research Questions
How can cross-reactivity issues with My-1 Antibody be resolved in complex samples?
Cross-reactivity due to epitope similarity (e.g., myeloid vs. lymphoid markers) requires:
What experimental strategies address contradictory data in My-1 expression studies?
-
Context-dependent variability: My-1 expression may fluctuate with granulocyte activation states; use paired samples (resting vs. cytokine-stimulated) .
-
Technical controls: Include isotype-matched antibodies and FMO (fluorescence minus one) controls in flow cytometry .
-
Meta-analysis: Compare results across platforms (e.g., RNA-seq vs. protein-level data) to resolve discrepancies .
How can hybridoma generation for My-1-like antibodies be optimized?
Recent advancements in hybridoma workflows include:
| Parameter | Traditional Approach | Improved Strategy |
|---|---|---|
| Fusion partner | P3-X63Ag8 (low yield) | SP2/0 myeloma cells (higher stability) |
| Screening | Manual ELISA | Automated microfluidics + single-cell sequencing |
| Chimerization | Mouse-only frameworks | Human/mouse cross-reactive scaffolds (e.g., GNUV201 design) |
What computational tools enhance My-1 Antibody affinity maturation?
-
Protein language models (ESM-1v): Predict evolutionarily plausible mutations to improve binding kinetics .
-
Directed evolution pipelines: Combine in silico screening (e.g., ΔΔG calculations) with BLI (biolayer interferometry) for rapid KD validation .
-
Structural modeling: Map My-1 epitopes using AlphaFold2-predicted antigen structures to guide mutagenesis .
Methodological Notes
-
Antibody validation: Always pair My-1 with lineage-specific markers (e.g., MPO for granulocytes) to reduce false positives .
-
Data reporting: Use MIAME-compliant formats for flow cytometry and include raw binding curves in supplements .
-
Ethical compliance: For clinical samples, verify My-1’s non-reactivity with healthy lymphocytes to avoid misdiagnosis .
